Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,874.53 -1,986.27 (-3.16%) CMC Crypto 200
1,265.57 -92.44 (-6.81%)
Ardelyx, Inc. (ARDX)
After hours:
| Previous close | 8.06 |
| Open | 8.05 |
| Bid | 7.76 x 2100 |
| Ask | 7.81 x 1000 |
| Day's range | 7.59 - 8.11 |
| 52-week range | 3.16 - 10.13 |
| Volume | |
| Avg. volume | 6,048,869 |
| Market cap | 1.888B |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.28 |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.95 |
GlobeNewswireArdelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting IBSRELA® (tenapanor) will be presented at the 2024 Digestive Disease Week Conference (DDW), to be held May 18-21, 2024, in Washington, D.C. IBSRELA is approved by the U.S. Food and Drug Administration to
Insider MonkeyArdelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript
Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript May 2, 2024 Ardelyx, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.13. Ardelyx, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to the Ardelyx […]
Simply Wall St.Ardelyx First Quarter 2024 Earnings: Beats Expectations
Ardelyx ( NASDAQ:ARDX ) First Quarter 2024 Results Key Financial Results Revenue: US$46.0m (up 305% from 1Q 2023). Net...
